The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Self-citationPhan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575 · cited 1×
“Results of phase I/II studies in previously treated patients with metastatic melanoma show that ipilimumab induces antitumor responses when administered as monotherapy [13–17], and when combined with vaccine [18, 19] or IL-2 [20].”
BackgroundWolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Self-citationAttia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Self-citationHodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
Korn, E. L., Liu, P.-Y., Lee, S. J., Chapman, J.-A. W., Niedzwiecki, D., Suman, V. J., Moon, J., Sondak, V. K., Atkins, M. B., Eisenhauer, E. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7837 · Cited by 705
Immunotherapy and chemotherapy — a practical partnership
Lake, R. A., & Robinson, B. W. S. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1613 · Cited by 646
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
Bedikian, A. Y., Millward, M., Pehamberger, H., Conry, R., Gore, M., Trefzer, U., Pavlick, A. C., DeConti, R., Hersh, E. M., Hersey, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0483 · Cited by 600
Self-citationRibas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591 · cited 1×
“Durable responses with ipilimumab have been observed in other studies involving previously treated patients with advanced melanoma [17, 19], and have been observed in melanoma patients treated with the anti-CTLA-4 monoclonal antibody, tremelimumab [26].”
BackgroundWeber, J., Thompson, J. A., Hamid, O., Minor, D., Amin, A., Ron, I., Ridolfi, R., Assi, H., Maraveyas, A., Berman, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1024 · Cited by 568
Self-citationGlobal perspectives of contemporary epidemiological trends of cutaneous malignant melanoma
Lens, M. B., & Dawes, M. (2004) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2004.05708.x · Cited by 567
Maker, A. V., Phan, G. Q., Attia, P., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Haworth, L. R., Levy, C., et al. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.03.536 · Cited by 492
Self-citationPhase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Weber, J. S., O’Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., Snively, J., & Hersh, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1927 · Cited by 463 · cited 2×
“Moreover, as 2 of the 5 patients that survived well beyond 4 years had SD, the results of our study are consistent with previous reports [17] supporting SD as a clinically relevant endpoint for ipilimumab therapy in advanced melanoma.”
BackgroundResultSelf-citationFong, L., & Small, E. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.8954 · Cited by 323
Weber, J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-864 · Cited by 286
Self-citationIpilimumab: controversies in its development, utility and autoimmune adverse events
Weber, J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0653-8 · Cited by 224
Self-citationCurrent systemic therapy for metastatic melanoma
Agarwala, S. S. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.25 · Cited by 173
Single-agent interleukin-2 in the treatment of metastatic melanoma: A systematic review
Petrella, T. M., Quirt, I. C., Verma, S., Haynes, A. E., Charette, M. L., & Bak, K. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.04.003 · Cited by 87
Update on anti-CTLA-4 antibodies in clinical trials
Langer, L., Clay, T. M., & Morse, M. A. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.8.1245 · Cited by 80
Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative
Peggs, K. S., Segal, N. H., & Allison, J. P. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.023 · Cited by 79
Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.
Morse, M. A. (2005) · PubMed · Cited by 48
The Role of the CTLA4 Blockade in the Treatment of Malignant Melanoma
Cranmer, L. D., & Hersh, E. M. (2007) · Cancer Investigation · doi:10.1080/07357900701522315 · Cited by 48
Self-citationLin, R. K., Yellin, M. J., Lowy, I., Safferman, A. Z., Chin, K. M., & Ibrahim, R. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.9063 · Cited by 38
Self-citationO'Day, S. J., Ibrahim, R. A., DePril, V., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.9021 · Cited by 35
Self-citationAnti-CTLA-4 therapy in melanoma: role of ipilimumab (MDX-010)
Ridolfi, L., & Ridolfi, R. (2009) · Expert Review of Dermatology · doi:10.1586/edm.09.11 · Cited by 11
Moving forward with immunotherapy: the rationale for anti-CTLA-4 therapy in melanoma
Margolin, K. A. (2008) · Community Oncology · doi:10.1016/s1548-5315(11)70470-3 · Cited by 6
Cited by
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationIpilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091
Radiotherapy and immunotherapy: a beneficial liaison?
Weichselbaum, R. R., Liang, H., Deng, L., & Fu, Y.-X. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.211 · Cited by 1,070
Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Neal, J., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 1,002
Metadata
- Authors
- Hersh, E. M., O’Day, S. J., Powderly, J., Khan, K. D., Pavlick, A. C., Cranmer, L. D., Samlowski, W. E., Nichol, G. M., Yellin, M. J., & Weber, J. S.
- Venue
- Investigational New Drugs
- Published
- 2010-01-16
- Volume
- 29
- Issue
- 3
- Pages
- 489-498
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- OpenAlex
- W2040851929
- Cited by
- 307
- References
- 29
- FWCI
- 13.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.